Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04674683
Registration number
NCT04674683
Ethics application status
Date submitted
7/12/2020
Date registered
19/12/2020
Date last updated
27/07/2023
Titles & IDs
Public title
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
Query!
Scientific title
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors
Query!
Secondary ID [1]
0
0
HBI-8000-303
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Unresectable or Metastatic Melanoma
0
0
Query!
Progressive Brain Metastasis
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Cancer
0
0
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - HBI-8000 in combination with nivolumab
Treatment: Drugs - Placebo in combination with nivolumab
Experimental: Test Arm - HBI-8000 30 mg oral BIW + nivolumab IV at specific doses on specific days
Placebo Comparator: Control Arm - Placebo oral BIW + nivolumab IV at specific doses on specific days
Treatment: Drugs: HBI-8000 in combination with nivolumab
Patients will take 30 mg of HBI-8000 orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV will be administered by intravenous infusion at specific doses on specific days in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice. In adolescent patients with body weight < 40 kg, nivolumab will be dosed at specific doses on specific days.
Treatment: Drugs: Placebo in combination with nivolumab
Patients will take 30 mg of Placebo orally approximately 30 minutes after a full meal, beginning on Day 1 and continue every 3 to 4 days on the BIW schedule. On Day 1 of each cycle nivolumab IV at specific doses will be administered by intravenous infusion in accordance with OPDIVO® manufacturer regional product information insert and the institution's prescribing practice.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Primary Outcome
Query!
Assessment method [1]
0
0
Objective Response Rate (ORR) defined as the percentage of patients enrolled in each study arm with a best response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), as determined by the blinded independent review committee (BIRC).
Query!
Timepoint [1]
0
0
From date of randomization until disease progression or unacceptable toxicity, assessed up to 48 months
Query!
Primary outcome [2]
0
0
Primary Outcome
Query!
Assessment method [2]
0
0
Progression-free Survival (PFS) defined as the time from the date of randomization to the first date of documented disease progression as determined by BIRC, or the date of death due to any cause, whichever occurs first.
Query!
Timepoint [2]
0
0
From date of randomization to the earliest date of documented progressive disease (PD), assessed up to 48 months
Query!
Secondary outcome [1]
0
0
Secondary Outcome
Query!
Assessment method [1]
0
0
Overall Survival (OS) defined as the time from date of randomization to the date of death due to any cause.
Query!
Timepoint [1]
0
0
From date of randomization to death due to any cause, assessed up to 48 months
Query!
Secondary outcome [2]
0
0
Secondary Outcome
Query!
Assessment method [2]
0
0
Safety defined as incidence rate of adverse events (AEs), severity (CTCAE v.5.0), causal relationship assessment, and outcomes of reported AEs.
Query!
Timepoint [2]
0
0
From date of randomization until the end of study, assessed up to 48 months
Query!
Eligibility
Key inclusion criteria
1. Histopathologically confirmed diagnosis of non-uveal, Stage III (unresectable), or
Stage IV (metastatic) melanoma according to AJCC staging system (8th edition).
2. Known BRAF V600 mutation status or consent to BRAF V600 mutation testing before
randomization.
3. Tumor tissue available for PD-L1 testing at central lab. PD-L1 expression level is
required for randomization. In order to be randomized, a patient must be classified as
PD-L1 positive or PD-L1 negative according to the following criteria:
- PD-L1 positive (= 1% tumor cell membrane staining in a minimum of a hundred
evaluable tumor cells) vs
- PD-L1 negative (< 1% tumor cell membrane staining in a minimum of a hundred
evaluable tumor cells).
Note: If an insufficient amount of tumor tissue from an unresectable or metastatic
site is available prior to the start of the Screening Phase, patients must consent to
allow the acquisition of additional tumor tissue for assessment of the biomarker.
4. Males or females 12 years of age or older.
5. ECOG performance status =1 for age =18 years, Lansky performance score =80% for age 12
to 17 years.
6. At least one measurable lesion defined by RECIST 1.1 criteria, (separate from the
lesion to be used for tumor tissue collection for PD-L1 testing) not counting brain
metastasis with:
- Longest diameter =10 mm by CT (when slice thickness is =5 mm); or = 2× slice
thickness (when slice thickness is >5 mm)
- Pathologically enlarged lymph node: =15 mm in short axis by CT (when slice
thickness is =5 mm)
- Clinical: =10 mm (that can be accurately measured with calipers).
7. Have not received anti-PD-1, anti-PD-L1 or other systemic therapy for unresectable or
metastatic melanoma, except for the following, provided that the patient has recovered
from all treatment-related toxicities:
- BRAF mutation targeting therapy > 4 weeks before administration of Study
Treatment.
- Adjuvant or neoadjuvant therapy with PD-1 or PD-L1 inhibitors or anti-CTLA-4) is
allowed if disease progression/or recurrence occurred at least 6 months after the
last dose and no clinically significant immune related toxicities leading to
treatment discontinuation were observed
- Adjuvant interferon therapy must have been completed > 6 weeks before
administration of Study Treatment
8. Any prior radiotherapy or minor surgery must be completed at least 2 weeks and 1 week
respectively before Day 1 dosing and recovered from all treatment related toxicities
9. Screening laboratory results within 14 days prior to randomization:
- Hematology: WBC =3000/µL, neutrophils =1500/µL, platelets =100 × 103/µL,
hemoglobin =10.0 g/dL independent of transfusion. The use of erythropoietic
growth factor to achieve hemoglobin (Hgb) = 10 g/dl is acceptable.
- The CrCL= 30 mL/min using Cockcroft-Gault formula.
- AST and ALT =3 × ULN, alkaline phosphatase =2.5 × ULN unless bone metastases
present (patients with documented bone metastases: alkaline phosphatase <5 x
ULN), bilirubin = 1.5 × ULN (unless known Gilbert's disease where it must be = 3
× ULN), serum albumin = 3.0 g/dL).
10. Negative serum pregnancy test at baseline for women of childbearing potential.
11. Females of childbearing potential (non-surgically sterile or premenopausal female
capable of becoming pregnant) and all males (due to potential risk of drug exposure
through the ejaculate) must agree to use adequate birth control measures from study
start, during the study and for 5 months after the last dose of Study Drug. Acceptable
methods of birth control in this trial include two highly effective methods of birth
control (as determined by the Investigator; one of the methods must be a barrier
technique) or abstinence.
12. Have the ability to understand and the willingness to sign a written informed consent
document, comply with study scheduled treatment, visits and assessments.
Query!
Minimum age
12
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. History of = Grade 3 hypersensitivity reactions to monoclonal antibodies.
2. Previous treatment with a PD-1, PD-L1, PD-L2, CTLA-4 inhibitor, or any other agents
targeting T-cell co-stimulation or immune checkpoint pathways for unresectable or
metastatic melanoma.
3. History of a cardiovascular illness including: congestive heart failure (New York
Heart Association Grade III or IV); unstable angina or myocardial infarction within
the previous 6 months; or symptomatic cardiac arrhythmia despite medical management.
QT interval corrected by heart rate using QTcF >450 ms in males or >470 ms in females,
or congenital long QT syndrome.
4. Uncontrolled hypertension, systolic blood pressure (SBP) >160 mmHg or diastolic blood
pressure (DBP) >100 mmHg.
5. Patients with new, active, or progressive brain metastases or leptomeningeal disease
with except when considered for a separate special open-label cohort described in
protocol Section 5.3 or "Inclusion of Patients with Progressive Brain Metastasis"
section in the protocol synopsis.
6. History of hemorrhagic diarrhea, inflammatory bowel disease, active uncontrolled
peptic ulcer, or bowel resection that affects absorption of orally administered drugs.
7. Active, known, or suspected autoimmune disease, except for Type I diabetes mellitus,
hypothyroidism requiring only hormone replacement, or skin disorders (such as
vitiligo, psoriasis, or alopecia) not requiring systemic therapy.
8. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy.
9. Known history of testing positive for HIV, known AIDS.
10. Hepatitis B surface antigen positive or hepatitis C antibody positive. Further
investigation per institutional practices may be performed to exclude active
infection.
11. Patients with a condition requiring chronic systemic treatment with either
corticosteroids (>10 mg daily prednisone or equivalents) or other immunosuppressive
medications within 14 days before administration of Study Treatment. Inhaled or
topical steroids, or adrenal replacement dose of corticosteroids at dose = 10 mg/day
prednisone equivalent are permitted.
12. Use of another investigational agent (drug or vaccine not marketed for any indication)
28 days or before administration of Study Treatment. If the investigational agent is a
monoclonal antibody then within 3 months before administration of Study Treatment
13. Pregnant or breast-feeding women.
14. Second malignancy unless in remission for 2 years or locally curable cancers that have
been treated with curative intent with no evidence of recurrence, such as:
- Basal or squamous cell skin cancer
- Superficial bladder cancer
- Carcinoma in situ of cervix or breast
- Incidental prostate cancer
- Non melanomatous skin cancer
- Carcinoma in situ of the cervix treated with curative intent
- Prostate cancer treated with curative intent with serum prostate specific antigen
(PSA) < 2.0 ng/mL
15. Patients with medical conditions requiring administration of strong cytochrome P450
(CYP), CYP3A4 Inducers and Inhibitors.
16. Uncontrolled adrenal insufficiency or active chronic liver disease.
17. Has received approved live vaccine/live attenuated vaccines within 30 days of planned
Cycle 1 Day 1. Inactivated viral vaccines or vaccines based upon subviral component
are allowed; however intranasal influenza vaccines (e.g. Flu-Mist) are not allowed.
COVID-19 vaccination should be administered at least 7 days before Cycle 1 Day 1.
18. Underlying medical conditions that, in the Investigator's opinion, will make the
administration of Study Treatment hazardous or obscure the interpretation of toxicity
determination or AEs.
19. Unwilling or unable to comply with procedures required in this protocol.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/08/2021
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/10/2025
Query!
Actual
Query!
Sample size
Target
480
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Query!
Recruitment hospital [1]
0
0
Sydney Adventist Hospital - Wahroonga
Query!
Recruitment hospital [2]
0
0
University of the Sunshine Coast - Buderim
Query!
Recruitment hospital [3]
0
0
University of the Sunshine - Sippy Downs
Query!
Recruitment hospital [4]
0
0
Icon Cancer Centre Wesley - South Brisbane
Query!
Recruitment hospital [5]
0
0
Ballarat Health Services - Ballarat
Query!
Recruitment hospital [6]
0
0
Goulburn Valley Health - Shepparton
Query!
Recruitment hospital [7]
0
0
Royal Brisband and Women's Hospital - Brisbane
Query!
Recruitment hospital [8]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [9]
0
0
Affinity Clinical Research - Nedlands
Query!
Recruitment hospital [10]
0
0
Tweed Hospital - Tweed Heads
Query!
Recruitment hospital [11]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment postcode(s) [1]
0
0
- Wahroonga
Query!
Recruitment postcode(s) [2]
0
0
4556 - Buderim
Query!
Recruitment postcode(s) [3]
0
0
4556 - Sippy Downs
Query!
Recruitment postcode(s) [4]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [5]
0
0
- Ballarat
Query!
Recruitment postcode(s) [6]
0
0
- Shepparton
Query!
Recruitment postcode(s) [7]
0
0
- Brisbane
Query!
Recruitment postcode(s) [8]
0
0
- Liverpool
Query!
Recruitment postcode(s) [9]
0
0
- Nedlands
Query!
Recruitment postcode(s) [10]
0
0
- Tweed Heads
Query!
Recruitment postcode(s) [11]
0
0
- Waratah
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Indiana
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Kentucky
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Montana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
North Carolina
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Ohio
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
South Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Utah
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Virginia
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Wisconsin
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Graz
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Innsbruck
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Brasschaat
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Brussels
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Ghent
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Hasselt
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Liège
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Ottignies
Query!
Country [24]
0
0
Brazil
Query!
State/province [24]
0
0
Bahia
Query!
Country [25]
0
0
Brazil
Query!
State/province [25]
0
0
Paraná
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Rio Grande Do Sul
Query!
Country [27]
0
0
Brazil
Query!
State/province [27]
0
0
Sao Paulo
Query!
Country [28]
0
0
Brazil
Query!
State/province [28]
0
0
São Paulo,
Query!
Country [29]
0
0
Brazil
Query!
State/province [29]
0
0
São Paulo
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Olomouc
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Ostrava-Poruba
Query!
Country [32]
0
0
Czechia
Query!
State/province [32]
0
0
Prague
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Besançon
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Boulogne-Billancourt
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Dijon
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
La Tronche
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Lille
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Marseille
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Paris
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Pierre-Bénite
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Rouen
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Villejuif
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Dresden,
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Erfurt
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Essen
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Freiburg
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Heidelberg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Koeln
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Leipzig
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Luebeck
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Mainz
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Mannheim
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Tuebingen
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Milano
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Bari
Query!
Country [57]
0
0
Italy
Query!
State/province [57]
0
0
Bologna
Query!
Country [58]
0
0
Italy
Query!
State/province [58]
0
0
Misterbianco
Query!
Country [59]
0
0
Italy
Query!
State/province [59]
0
0
Napoli
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Palermo
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Perugia
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Roma
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Siena
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Verona
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Nagano
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Osaka
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Sunto-gun
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Tokho
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Fukuoka
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Niigata
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Okayama
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Gyeonggi-do
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Gyeonggi
Query!
Country [74]
0
0
Korea, Republic of
Query!
State/province [74]
0
0
Jeollanam-do
Query!
Country [75]
0
0
Korea, Republic of
Query!
State/province [75]
0
0
Jung-gu
Query!
Country [76]
0
0
Korea, Republic of
Query!
State/province [76]
0
0
Seoul
Query!
Country [77]
0
0
New Zealand
Query!
State/province [77]
0
0
Auckland
Query!
Country [78]
0
0
New Zealand
Query!
State/province [78]
0
0
Hamilton
Query!
Country [79]
0
0
New Zealand
Query!
State/province [79]
0
0
Tauranga
Query!
Country [80]
0
0
Puerto Rico
Query!
State/province [80]
0
0
Rio Piedras
Query!
Country [81]
0
0
Singapore
Query!
State/province [81]
0
0
Singapore
Query!
Country [82]
0
0
South Africa
Query!
State/province [82]
0
0
Gauteng
Query!
Country [83]
0
0
South Africa
Query!
State/province [83]
0
0
Western Cape
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Barcelona
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Madrid
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Málaga
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Sevilla
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Zaragoza
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Hampshire
Query!
Country [90]
0
0
United Kingdom
Query!
State/province [90]
0
0
Edinburgh
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
HUYABIO International, LLC.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Bristol-Myers Squibb
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined
with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who
are not adolescents or patients with new, progressive brain metastasis will be stratified by
PD-L1 expression and LDH level.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04674683
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
John T Ning, MD, PhD
Query!
Address
0
0
HUYABIO International, LLC.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
M Tawashi
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-858-209-1695
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04674683
Download to PDF